

1. [Torrent, Intas join fray for teva products in Europe](#) – The Economic Times

Torrent Pharmaceuticals and Temasek-backed Intas are the latest to join the race to acquire a band of products in Europe put on the block by Teva, the world's largest generic drug maker. The deal, said to be valued up to \$1.5 billion, has seen the Hyderabad based Aurobindo Pharma emerge as one of the front runners in the initial rounds.

2. [Submit licence application data within 45 days](#): DCGI – Business Standard

Taking a grim view of incomplete applications, which ultimately delays the licence-approval process, the Drugs Controller General of India (DCGI) has decided on a time limit of 45 days for supplementary clarifications or information, whenever asked for. If the companies do not give such information within 45 days, DCGI would dispose of such applications with the incomplete data. "It will be presumed that the applicant does not intend to pursue its application further," DCGI said.

3. [New HIV drugs lock virus in immaturity](#) – The Financial Express

A team of researchers has found that a new type of HIV drug, currently being tested, works in an unusual way. Scientists in the Molecular Medicine Partnership Unit also discovered that when the virus became resistant to early versions of these drugs, it did not do so by blocking or preventing their effects, but rather by circumventing them.

4. [Brexit impact on India: Nirmala Sitharaman explains key features](#) – The Financial Express

Commerce and industry minister Nirmala Sitharaman says Britain wants informal talks on a likely trade pact with India to continue until its exit process with the EU is over. In an interview with Banikinkar Pattanayak and Shobhana Subramanian, Sitharaman says the export slowdown has bottomed out, and her ministry is in regular talks with the finance ministry to offer relief to struggling SEZs.

1. [Torrent, Intas join fray for teva products in Europe](#) – The Economic Times
2. [Submit licence application data within 45 days](#): DCGI – Business Standard
3. [New HIV drugs lock virus in immaturity](#) – The Financial Express
4. [Brexit impact on India: Nirmala Sitharaman explains key features](#) – The Financial Express
5. [Healthcare at cost of property for poor, finds study](#) – The Times of India
6. [City exporters see growth in exports after 1.5 year, seek incentives from government](#) – The Times of India
7. [Fujifilm Pharma to launch diabetes product in Japan](#) – The Times of India
8. [Eye infection: PGI files plaint with drug controller](#) – Hindustan Times
9. [Medical device sector: draft rules classify instruments](#) – Deccan Herald
10. [Precision Medicine - A breakthrough in cancer treatment : Dr Meenu Walia](#) –ET Healthworld.com
11. [PPR 2015 will become part of curriculum of all pharmacy courses from D Pharm to Pharm D shortly](#) – Pharmabiz.com
12. [Pharma exports to US, Europe decline by 7% in first quarter, Pharmexcil to hold meeting with exporters](#) – Pharmabiz.com
13. [DoP directs NPPA to examine new data to review ceiling price of erythropoietin Inj 2000 IU & 10000 IU](#) – Pharmabiz.com
14. [UGC suggests adding IPR in UG-PG Syllabus](#) – The Hitavada

5. [Healthcare at cost of property for poor, finds study](#) – **The Times of India**
A recent study undertaken by the Budget Analysis Rajasthan Centre in collaboration with NGOs Prayas and the Jan Swasthya Abhiyan has shown that the budgetary allocation for health in Rajasthan is between 4.5% and 6.8% of the total budget. Not only is this woefully inadequate, what money is available is often not fully utilized.
6. [City exporters see growth in exports after 1.5 year, seek incentives from government](#) – **The Times of India**
Responding to the trade data for the month of June according to which 1.27 per cent growth has been witnessed in India's exports after continuous decline for past 18 months, city exporters are hopeful that things will change in time to come for exporters who are in distress specially due to drop in orders and currency fluctuations, provided government takes concrete steps to support the businessmen.
7. [Fujifilm Pharma to launch diabetes product in Japan](#) – **The Times of India**
Biocon on Saturday announced that its partner Fujifilm Pharma Co would launch bio-similar product Insulin Glargine in Japan after receiving approval from the Japanese health authority earlier this year. In the BSE filing Biocon said, "Close on the heels of receiving approval for its Insulin Glargine from the Japanese regulator last year, its partner Fujifilm Pharma Co has launched the product in Japan today."
8. [Eye infection: PGI files plaint with drug controller](#) – **Hindustan Times**
The Post Graduate Institute of Medical Education and Research (PGIMER) filed a complaint with the Drug Controller General of India (DCGI) on Saturday, after 27 of 30 patients injected with Avastin injection developed infection at its Advanced Eye Centre (AEC). The complaint includes a report prepared by Dr AK Jain, acting head, ophthalmology department; request for purchase of Avastin drug; and the cash memo showing that the drug was bought from a local chemist, Kumar and Company.
9. [Medical device sector: draft rules classify instruments](#) – **Deccan Herald**
The Medical Device Rules, 2016, suggest categorisation of medical devices into four groups depending on the risks associated with the device. Those with the least risk, such as syringes, wheelchairs or walking sticks would come under category-A, whereas implantable devices like stents or pacemakers would be considered category-D instruments. Pre-printed MRP: In a parallel exercise, the government also decided to change the existing consumer protection rules to ensure that each individual medical device carries a pre-printed MRP (maximum retail price) tag rather than a price sticker on the entire box of these devices.
10. [Precision Medicine - A breakthrough in cancer treatment : Dr Meenu Walia](#) –**ET Healthworld.com**
In an interview with Director of Max Oncology at Max hospital, Patparganj, Dr Meenu Walia talks about role of precision medicine in cancer treatment. She is the first DNB medical oncologist of India who has been the Principal Investigator of several Multi-Centric International Clinical Research trials where newer options for Cancer treatment are evaluated.
11. [PPR 2015 will become part of curriculum of all pharmacy courses from D Pharm to Pharm D shortly](#) – **Pharmabiz.com**
The Pharmacy Practice Regulations (PPR) 2015 introduced by the Pharmacy Council of India for regulating the profession of pharmacy will shortly become part of the syllabus of all pharmacy courses in the country. PCI is working on to make the PPR a comprehensive study paper in the syllabuses of the courses from D Pharm to M Pharm and for the doctoral program, Pharm D. The regulations got due importance in the revised syllabus of the diploma in pharmacy course, which will be introduced throughout the country shortly, according to the president of PCI. Dr. B. Suresh, president of PCI, said all the regulations of the pharmacy council of India are framed under the Pharmacy Act 1948. The syllabuses of D Pharm and B Pharm courses include the

pharmacy act and the regulations framed under there, and the students study them under the subjects, Forensic Pharmacy and Pharmaceutical Jurisprudence. However, emphasis will be given on the new pharmacy practice regulations to be part of the curriculum.

12. [Pharma exports to US, Europe decline by 7% in first quarter, Pharmexcil to hold meeting with exporters – Pharmabiz.com](#)

The Indian Pharma export has witnessed 6 to 7 per cent negative growth in Europe and US market in last three months. The Pharmaceuticals Export Promotion Council (Pharmexcil) will organise an interactive meeting with joint secretary (JS) of the department of commerce (DoC) to discuss the reason behind the decline. The Council plans to hold an interactive meet of the top exporters to US and Europe market with Sudhanshu Pandey, joint secretary, department of commerce on August 29, 2016 at Hotel The Lalit, Mumbai. "With concentration in US market, Russia and Africa fluctuation in the exchange rate is a major issue for the decline. In European market the decline in pharma export was due to the issues related to written confirmation certificate but with the help of DCGI that issue has been addressed. The Pharmexcil will share the export performance report at the meeting and will discuss the issues and suggestion shared by the exporters."

13. [DoP directs NPPA to examine new data to review ceiling price of erythropoietin Inj 2000 IU & 10000 IU – Pharmabiz.com](#)

The Department of Pharmaceuticals (DoP) has directed the National Pharmaceutical Pricing Authority (NPPA) to examine any relevant data furnished by Wockhardt for reviewing the ceiling prices of Erythropoietin Injection 2000 IU and 10000 IU. The NPPA through its notification No. S.O. No.1405(E) dated 12.04.2016 had fixed the ceiling prices of erythropoietin Injection 2000 IU and 10000 IU. Aggrieved by the notification, Wockhardt submitted a review application under paragraph 31 of the DPCO against NPPA order No. S.O. 1405(E) dated 12/04/2016 for price fixation of erythropoietin Injection 2000 IU and 10000 IU.

14. [UGC suggests adding IPR in UG-PG Syllabus – The Hitavada](#)

Keeping in view the importance of intellectual property rights (IPR), which recognises the work of creator, University Grants Commission directed academic council and private institutions to devise inclusion of the topic as a generic elective subject under the Choice Based Credit System (CBCS). The commission has suggested to include IPR in syllabus of universities and affiliated colleges so that student would get aware of its importance. According to UGC, creations of mind such as inventions, designs for industrial articles, literary, artistic work, symbols, names and images etc are protected by intellectual property rights (IPR). It is normally of two type industrial property rights and copyright. The importance of IPR was first recognized in Paris convention for the protection of industrial property (1883) and the Berne Convention for Protection of Literary and Artistic Work (1886). UGC said IPR should be protected to encourage the creator and also striking a balance between the innovators and public interest by creating awareness where creativity can flourish.